Equity Profile

ACAD

ACADIA Pharmaceuticals Inc.

Health CareBiotechnology$3.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to gauge market demand for ACAD's products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders. With a market cap of $4 billion, its work is particularly relevant as mental health and neurological conditions gain increasing attention in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, ACAD reported an EPS of $0.02, which was below the expected $0.04, resulting in a stock decline of 3.89% the following day. The company has shown mixed performance in recent quarters, with some significant surprises.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for ACAD's upcoming earnings are cautious, given the recent EPS miss and lack of analyst estimates. Investors are eager to see if the company can return to a growth trajectory.

Bull Case

If ACAD can deliver better-than-expected EPS and show strong revenue growth, it could signal a recovery and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its ability to execute and lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the recent EPS miss, the market will be closely watching for any signs of improvement in profitability.

How is revenue trending this quarter?

Revenue growth is critical for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ACAD to rebound from its last earnings miss, as historical trends show strong recovery patterns after similar situations.

Supporting Evidence

ACAD has an 88% EPS beat rate historically, suggesting a strong likelihood of exceeding expectations.

The options market is pricing in a significant move, indicating that traders expect a more volatile reaction than usual.

Insider selling may suggest a lack of confidence, but it could also be a strategic move unrelated to company performance.

Key Risk

If the EPS comes in above $0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a disappointing EPS report, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case, raising concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$690,249.35

31,986 sh

5 insiders

Net

$690,249.35

Net selling

Most Active Insiders· 11 open-market trades

EVP, CHIEF FINANCIAL OFFICERSchneyer Mark C.
$219,275.68

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACAD beats expectations, history suggests a potential stock increase of around 1.98%, confirming a positive turnaround.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors weigh management's commentary against expectations.

Miss

If the company misses again, history suggests a potential decline of about 3.89%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand for existing products.
3Insights into cost management and operational efficiency.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to questions about competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to gauge market demand for ACAD's products and overall business performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for ACAD's upcoming earnings are cautious, given the recent EPS miss and lack of analyst estimates. Investors are eager to see if the company can return to a growth trajectory.

Bull Case

If ACAD can deliver better-than-expected EPS and show strong revenue growth, it could signal a recovery and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its ability to execute and lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the recent EPS miss, the market will be closely watching for any signs of improvement in profitability.

How is revenue trending this quarter?

Revenue growth is critical for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ACAD to rebound from its last earnings miss, as historical trends show strong recovery patterns after similar situations.

Supporting Evidence

ACAD has an 88% EPS beat rate historically, suggesting a strong likelihood of exceeding expectations.

The options market is pricing in a significant move, indicating that traders expect a more volatile reaction than usual.

Insider selling may suggest a lack of confidence, but it could also be a strategic move unrelated to company performance.

Key Risk

If the EPS comes in above $0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a disappointing EPS report, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS of $0.10 or better would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case, raising concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$690,249.35

31,986 sh

5 insiders

Net

$690,249.35

Net selling

Most Active Insiders· 11 open-market trades

EVP, CHIEF FINANCIAL OFFICERSchneyer Mark C.
$219,275.68

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACAD beats expectations, history suggests a potential stock increase of around 1.98%, confirming a positive turnaround.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors weigh management's commentary against expectations.

Miss

If the company misses again, history suggests a potential decline of about 3.89%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand for existing products.
3Insights into cost management and operational efficiency.
4Guidance on revenue expectations for the upcoming quarters.
5Responses to questions about competitive pressures in the biotechnology sector.